SMYD2 inhibition–mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity
Science Advances · 2023-06-16 · 9 (24)
DOI: 10.1126/sciadv.ade6624 ↗At a glance
Journal article in Science Advances, published on 2023-06-16. Written by Ming Tang and 10 co-authors. Institution: Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Clinical and Translationa…. Major MEDLINE topics: CD8-Positive T-Lymphocytes, DNA End-Joining Repair, Ku Autoantigen, Histone-Lysine N-Methyltransferase. Cited 37 times so far (Crossref); 55 references. The full text is freely available in PubMed Central.
Abstract (original language)
DNA damage repair (DDR) is a double-edged sword with different roles in cancer susceptibility and drug resistance. Recent studies suggest that DDR inhibitors affect immune surveillance. However, this phenomenon is poorly understood. We report that methyltransferase SMYD2 plays an essential role in nonhomologous end joining repair (NHEJ), driving tumor cells adaptive to radiotherapy. Mechanically, in response to DNA damage, SMYD2 is mobilized onto chromatin and methylates Ku70 at lysine-74, lysine-516, and lysine-539, leading to increased recruitment of Ku70/Ku80/DNA-PKcs complex. Knockdown of SMYD2 or its inhibitor AZ505 results in persistent DNA damage and improper repair, which sequentially leads to accumulation of cytosolic DNA, and activation of cGAS-STING pathway and triggers antitumor immunity via infiltration and activation of cytotoxic CD8 + T cells. Our study reveals an unidentified role of SMYD2 in regulating NHEJ pathway and innate immune responses, suggesting that SMYD2 is a promising therapeutic target for cancer treatment.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Schoo…
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.
- Guangdong Key Laboratory of Genome Instability and Human Disease, Shenzhen University International Cancer Center, Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518055, C…
ORCID profiles: Ming Tang, Guofang Chen, Bo Tu, Yongzhong Liu, Wei-Guo Zhu, Wen Lu
Cite
APA
Tang, M., Chen, G., Tu, B., Hu, Z., Huang, Y., DuFort, C. C., Wan, X., Mao, Z., Liu, Y., Zhu, W. G., & Lu, W. (2023). SMYD2 inhibition–mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity. Science Advances, 9(24). https://doi.org/10.1126/sciadv.ade6624
Vancouver
Tang M, Chen G, Tu B, Hu Z, Huang Y, DuFort CC, et al. SMYD2 inhibition–mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity. Science Advances. 2023;9(24). doi:10.1126/sciadv.ade6624
BibTeX
@article{Tang2023,
author = {Tang, Ming and Chen, Guofang and Tu, Bo and Hu, Zhiyi and Huang, Yujia and DuFort, Christopher C and Wan, Xiaoping and Mao, Zhiyong and Liu, Yongzhong and Zhu, Wei-Guo and Lu, Wen},
title = {SMYD2 inhibition–mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {24},
doi = {10.1126/sciadv.ade6624}
}
EUVIMED